AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Diversifying crypto investments effectively can boost your returns. Discover essential techniques for a stronger portfolio.
19,398 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Marbella unveiled a bold 2.0 strategy to pivot from luxury tourism to a European tech hub, courting startups and inte...
Public disclosures show surprising activity in major names, but smart investing hinges on fundamentals, risk, and a d...
Mitsubishi closed a $7.5 billion acquisition of Aethon Energy's U.S. gas assets, creating Adamas Energy in Dallas. Th...
IBM’s dramatic one-day plunge coincided with blockbuster bank profits, fueling a debate over whether markets are misp...
Two leading space-focused stocks pull investors in different directions. Learn how the spacemobile rocket lab: number...
Jim Cramer tells CNBC’s Mad Money Investing Club to sell Oracle and avoid liquor stocks, outlining a mix of defensive...
Interactive Brokers grew customer accounts by 34% in the last year, signaling strong momentum in a competitive discou...
A high-stakes debate is unfolding around SpaceX and its heavy short interest. This article breaks down what it means ...
As the U.S. ramps up nuclear capacity, one stock could benefit from policy shifts, domestic fuel security, and growin...
The final BEA report for 2025 shows stronger-than-expected growth across consumption and investment, setting a positi...
Institutional moves can illuminate a stock's future. This article unpacks what it means when an investment manager be...